Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim International Pharma Gmbh & Co. Kg

Anke Baum

Flavio Solca

Martin Steegmaier

Frank Himmelsbach

Birgit Jung

Elke Langkopf

Matthias Grauert

Jacobus C A Van Meel

Florian Colbatzky

Jens Juergen Quant

Matthias Hoffmann

Heinz Stadtmueller

Stefan Matthias Blech

Gerd Stehle

Gisela Schnapp

Andree Amelsberg

Christian Eickmeier

Steffen Breitfelder

Harald Engelhardt

Trixi Brandl

Stephan Karl Zahn

Thomas Metz

Gerd Michael Munzert

Jens Jurgen Quant

Marco Santagostino

Tobias Wunberg

Rudolf Hauptmann

Juergen Ramharter

Markus Ostermeier

Ulrich Reiser

Andreas Schoop

Karl-Heinz Heider

Frank Hilberg

Christiane Kofink

Dorothea Ingrid Rudolph

Markus Frank

Stefan Goepper

Annika Gille

Guido Boehmelt

Ulrich Guertler

Marco Hans Hofmann

Matthias Hoffman

Michael Gmachl

Julian Wippich

Lars Herfurth

Charlotte Astrid Russell

Fabio Savarese

Jacobus CA Van Meel

Stefan Blech

Jens Quant

Jacobus Ca Van Meel

Jacobus C Van Meel

Martin Friedrich Stefanic

The present invention encompasses compounds of formula (1) wherein the groups Rto R, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors

The present invention relates to the use of quinazolines of formula (I), wherein the groups Rto Rhave the meanings given in the claims and specification, in cancer therapy.

Quinazoline derivatives for the treatment of cancer diseases

The present invention relates to immunotherapies that are based on depletion of CD37-positive cells such as B-cells. The present invention provides methods for reduction of CD37-positive cells such as B-cells in an individual/patient using a combination of CD37 antibody/antibodies and ICE. The combination of CD37 antibodies and ICE is shown to have improved anti-tumor efficacy compared to single agent treatment. The application further provides materials and methods for treatment of diseases involving aberrant B-cell activity.

Combination of CD37 antibodies with ICE

The present invention relates to bicyclic heterocycles of general formula wherein

Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them

Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I)  wherein the groups L, R, R, R, Rand Rhave the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Combinations for the treatment of diseases involving cell proliferation

Quinazoline derivatives and pharmaceutical compositions containing them

The present invention relates to the use of quinazolines of formula (I), wherein the groups Rto Rhave the meanings given in the claims and specification, in cancer therapy. 

Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R, R, R, Rand Rhave the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Dihydropteridinone compounds

The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis

Methods for treating diseases or conditions using dihydropteridinone compounds

Disclosed are dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the pharmaceutical compositions, isomers, intermediates thereof and processes for preparing these dihydropteridinones. The compounds are useful the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.

Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same

The present invention encompasses compounds of general formula (1) wherein

2,4-diaminopyrimidines useful for treating cell proliferation diseases

Growing community of inventors

Vienna, Austria

Anke Baum